journal article·2026-06Open access

In situ biomimetic near-infrared fluorescent protein formed by tumor signature proteins for detecting breast cancer biopsy

Jianing Cheng, Taiyu Liu, Xintong Zhu, Chengbin Zhang, Yin Li, Mengxin Li, Dong Song, Jia Li, Feiran Zhang, Shoujun Zhu

Abstract

Intraoperative rapid diagnosis of breast cancer biopsies currently relies on frozen section pathology or rapid immunohistochemistry. However, the accuracy of these methods is often compromised due to morphological alterations during the freezing process and the limitations of antibody selection inherent to rapid immunohistochemistry (antigen-antibody reactions). To address these issues, we develop a tumor-selective dye that binds in situ to tumor signature proteins, forming biomimetic near-infrared fluorescent proteins (NIR-FPs) with much-enhanced brightness. This approach effectively illuminates the tumor region for rapid and accurate identification. The tumor-selective dye inserts into the pockets of tumor signature proteins, then covalently binds with the –SH group of the protein, resulting in a series of NIR-FPs. By combining this with three-dimensional histological electrophoresis, we can select specific molecular weight layers of NIR-FPs (labeled tumor signature proteins) to accurately determine tumor margins. When integrating with the high-throughput 40×40 microwell array module, our system demonstrates excellent diagnostic accuracy in processing smaller puncture biopsy specimens. Moreover, the alkyne group in the dye facilitates proteomics analysis of all tumor signature proteins captured by the tumor-selective dye, providing valuable information for identifying new targets for tumor detection.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Advanced Fluorescence Microscopy Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (74)

Show source-provided references
1. Awareness and current knowledge of breast cancer10.1186/s40659-017-0140-9 ↗
2. Current and future burden of breast cancer: global statistics for 2020 and 204010.1016/j.breast.2022.08.010 ↗
3. Current state of breast cancer diagnosis, treatment, and theranostics10.3390/pharmaceutics13050723 ↗
4. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
5. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 202010.1097/CM9.0000000000001474 ↗
6. Global patterns and trends in breast cancer incidence and mortality across 185 countries10.1038/s41591-025-03502-3 ↗
7. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 202010.1002/cac2.12207 ↗
8. Global challenges and policy solutions in breast cancer control10.1016/j.ctrv.2022.102339 ↗
9. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis
10. Emerging technologies for real-time intraoperative margin assessment in future breast-conserving surgery10.1002/advs.201901519 ↗
11. In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications10.1186/s12951-022-01648-7 ↗
12. Near-infrared luminescence high-contrast in vivo biomedical imaging10.1038/s44222-022-00002-8 ↗
13. Spatial mapping of protein composition and tissue organization: a primer for multiplexed antibody-based imaging10.1038/s41592-021-01316-y ↗
14. High-plex immunofluorescence imaging and traditional histology of the same tissue section for discovering image-based biomarkers10.1038/s43018-023-00576-1 ↗
15. Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers10.1111/his.12298 ↗
16. Deep Learning-Based H-Score quantification of immunohistochemistry-stained images10.1016/j.modpat.2023.100398 ↗
17. Best practices recommendations for diagnostic immunohistochemistry in lung cancer10.1016/j.jtho.2018.12.005 ↗
18. Deep-learning based breast cancer detection for cross-staining histopathology images
19. An enzyme-activatable aggregation-induced-emission probe: intraoperative pathological fluorescent diagnosis of pancreatic cancer via specific cathepsin E
20. Review of immunohistochemistry techniques: applications, current status, and future perspectives10.1053/j.semdp.2024.05.001 ↗
21. Intraoperative rapid immunohistochemistry with noncontact antibody mixing for undiagnosed pulmonary tumors10.1111/cas.15616 ↗
22. CODEX multiplexed tissue imaging with DNA-Conjugated antibodies10.1038/s41596-021-00556-8 ↗
23. Ten approaches that improve immunostaining: a review of the latest advances for the optimization of immunofluorescence10.3390/ijms23031426 ↗
24. Multimodal capture-antibody-independent lateral flow immunoassay based on AuNF-PMBA for point-of-care diagnosis of bacterial urinary tract infections10.1016/j.cej.2022.139021 ↗
25. Fluorescent proteins and their applications in imaging living cells and tissues10.1152/physrev.00038.2009 ↗
26. In vivo NIR-II fluorescence imaging for biology and medicine10.1038/s41566-024-01391-5 ↗
27. Fluorescent proteins and genetically encoded biosensors10.1039/D2CS00419D ↗
28. Super-stable cyanine@albumin fluorophore for enhanced NIR-II bioimaging10.7150/thno.71443 ↗
29. A genetic engineering strategy for editing near-infrared-II fluorophores10.1038/s41467-022-30304-9 ↗
30. Tumor receptor-seeking dyes for rapid intraoperative definition of tumor margin and histopathological morphology10.31635/ccschem.024.202303659 ↗
31. Biomimetic NIR-II fluorescent proteins created from chemogenic protein-seeking dyes for multicolor deep-tissue bioimaging10.1038/s41467-024-47063-4 ↗
32. NIR-II cyanine@albumin fluorophore for deep tissue imaging and imaging-guided surgery10.1002/smm2.1245 ↗
33. Site-specific labeling of proteins with Near-IR heptamethine cyanine dyes10.3390/molecules23112900 ↗
34. In situ albumin-hitchhiking NIR-II probes for accurate detection of micrometastases10.1021/acs.nanolett.3c01484 ↗
35. Molecular imaging of biological systems with a clickable dye in the broad 800-to 1,700-nm near-infrared window10.1073/pnas.1617990114 ↗
36. Chaperonin containing TCP1 subunit 5 is a tumor associated antigen of non-small cell lung cancer10.18632/oncotarget.19369 ↗
37. Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression10.1038/s41388-020-1279-3 ↗
38. Chaperonin containing TCP1 subunit 5 as a novel pan-cancer prognostic biomarker for tumor stemness and immunotherapy response: insights from multi-omics data, integrated machine learning, and experimental validation10.1007/s00262-025-04071-7 ↗
39. CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/β-catenin signalling pathway10.1038/s41416-022-01747-0 ↗
40. High expression of copine 1 promotes cell growth and metastasis in human lung adenocarcinoma
41. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer10.1002/mc.23177 ↗
42. Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma10.1038/modpathol.2008.147 ↗
43. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma10.1186/s12935-022-02485-2 ↗
44. CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer10.1186/s13046-018-0811-6 ↗
45. Hsa-miR-335 enhances cell migration and invasion in lung adenocarcinoma through targeting Copine-110.1002/mco2.93 ↗
46. FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth10.1158/0008-5472.CAN-10-0874 ↗
47. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS10.1002/ijc.32827 ↗
48. CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation10.1038/s41388-021-01739-z ↗
49. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-κB target genes by interaction with NFKBIZ10.1038/onc.2008.378 ↗
50. Homologous peptide foldamer promotes FUS aggregation and triggers cancer cell death10.1021/jacs.4c03420 ↗
51. Elevated FUS/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer
52. The expression profiles and prognostic values of HSPs family members in head and neck cancer10.1186/s12935-020-01296-7 ↗
53. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG10.1038/s41591-018-0309-y ↗
54. Frameshift mutations of HSPA4 and MED13 in gastric and colorectal cancers10.1007/s12253-016-0070-9 ↗
55. The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma10.1186/s12935-021-01987-9 ↗
56. HSPA4 knockdown retarded progression and development of colorectal cancer10.2147/CMAR.S310729 ↗
57. ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-to-mesenchymal transition10.1158/0008-5472.CAN-20-3543 ↗
58. ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment10.20892/j.issn.2095-3941.2022.0451 ↗
59. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism10.1038/s41589-023-01391-6 ↗
60. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction10.1016/j.ejca.2010.03.018 ↗
61. ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 110.1038/s43018-021-00299-1 ↗
62. CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO110.1038/s41419-019-2127-7 ↗
63. Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation10.1038/s41419-020-03174-6 ↗
64. A Hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer10.1158/0008-5472.CAN-14-1031 ↗
65. Blocking eIF5A modification in cervical cancer cells alters the expression of cancer-related genes and suppresses cell proliferation10.1158/0008-5472.CAN-13-0474 ↗
66. Deciphering colorectal cancer radioresistance and immune microrenvironment: unraveling the role of EIF5A through single-cell RNA sequencing and machine learning10.3389/fimmu.2024.1466226 ↗
67. Tumor-selective dye-based histological electrophoresis enables intraoperative tumor diagnosis via tumor-specific enhancement10.7150/thno.105500 ↗
68. Three-dimensional histological electrophoresis enables fast automatic distinguishment of cancer margins and lymph node metastases
69. Three-dimensional histological electrophoresis for high-throughput cancer margin detection in multiple types of tumor specimens10.1021/acs.nanolett.3c02206 ↗
70. Hydrogel pore-size modulation for enhanced single-cell Western blotting10.1002/adma.201503939 ↗
71. Single-cell western blotting10.1038/nmeth.2992 ↗
72. Metal reflector-enhanced thermoacoustic imaging as a guidance for puncture biopsy10.1142/S1793545824500147 ↗
73. A review on methods for diagnosis of breast cancer cells and tissues10.1111/cpr.12822 ↗
74. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies10.1186/1476-4598-5-24 ↗